Xenon製藥 XENE 深 滬
等待開盤 06-25 09:30:00 美东时间
55.58
+0.970
+1.78%
華盛通- 最 高56.55
- 今 開54.61
- 成交量 142.52万股
- 最 低 54.61
- 昨 收 54.61
- 總市值 537.27万
- 52周最高 63.95
- 市盈率 靜 --
- 換手率 1474.41%
- 52周最低 30.00
- 委 比 92.47%
- 總股本 9.67万
- 歷史最高 63.95
- 量 比 1.00
- 振 幅 3.55%
- 歷史最低 2.10
- 每 手 1
- 風險率 8.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger seizure reduction.
06-02 18:09
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to 10 new employees, including 32,750 share options and 19,200 RSUs, approved by the Compensation Committee on May 28, 2026. The share options have an exercise price of $54.79, vesting over four years, with 25% after one year and monthly thereafter. RSUs vest 25% annually over four years. Both grants are subject to the 2025 Inducement Equity Incentive Plan. Xenon focuses on developing ...
05-29 20:01
美股大行评级 | 潜在涨幅99.91%！Tigress Financial上调英伟达目标价至425美元，维持"强力买入"评级
今日重点评级关注：Tigress Financial：维持英伟达"强力买入"评级，目标价从360美元升至425美元；康托·菲茨杰拉德：维持DeFi Development"超配"评级，目标价从6美元升至7美元
05-28 19:00
JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $80 to $82.
05-27 21:51
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
Xenon Pharmaceuticals (($XENE)) has held its Q1 earnings call. Read on for the ...
05-09 09:24
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.
05-08 19:36
财报速睇 | Xenon制药 2026财年Q1营收0.00亿美元，同比下降100.0%；归母净利润亏损1.02亿美元，同比亏损扩大57.3%
华盛资讯5月8日讯，Xenon制药公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比下降100.0%，归母净利润亏损1.02亿美元，同比亏损扩大57.3%。
05-08 09:32
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals reported first...
05-08 05:50
